Tweet
the most important new 21 July 2015:
Scientists develop method to kill iPS-derived cells with high cancer risk
Researchers said July 21 they have found a way to eliminate cells derived from induced pluripotent stem (iPS) cells that have a high risk of becoming cancerous, a development that could lead to clinical applications of iPS cells.
“It is a totally new method that can remove cells that could turn cancerous,” said Kenichiro Kosai, a professor of gene therapy and regenerative medicine at Kagoshima University. “The technique could be used for clinical purposes in the field of regenerative medicine.”
pluripotent cells that fail to differentiate into a specific tissue are more likely to become cancerous, posing a grave problem for the clinical use of those cells.
Kosai and colleagues studied a gene known as survivin, which is activated in cancer cells. They discovered that survivin is also activated in iPS cells and ES cells that fail to develop into other cells.
The researchers created strains of a genetically modified virus that can proliferate and kill cells that contain survivin. Seven days after the modified virus was introduced into undifferentiated iPS cells and ES cells, all those cells died.
Meanwhile, cells that had turned into the specific tissue survived the introduction of the virus.
The research team will present its findings at a conference of the Japan Society of Gene Therapy on July 25 in Osaka."
That's a big big new, this will accelerate Tsuji, REgience, Keio univ, etc to enter human clinical trials
Other breaktroughts that will help, from only june/july 2015:
-New substrate opens door to mass produced regenerative thérapies
"Researchers at the University of Nottingham in the U.K., have found a synthetic substrate that can be used in the production of billions of stem cells.
Researchers at the University of Nottingham in the U.K. developed the cost-effective substrate that allows the growth of stem cells, and can also survive long-term storage.
"What we are doing here is paving the way for the manufacture of stem cells in large numbers when those therapies are proved to be safe and effective."
"The field of regenerative medicine has snowballed in the last five years and over the coming five years a lot more patients will be receiving stem cell treatments," Denning said. "Clinical trials are still in the very early stages. However, with this kind of product, if we can get it commercialized and validated by the regulators, it could be helping patients in two to three years." And he's from UK, not japan
- MicroRNA Switches Improve Cell Purification
Stem cell-based therapies usually require the differentiation of stem cells into various cell types that are used for regenerative therapies. Such a strategy requires that the differentiated cells be purified from the rest of the cells. Typically, cell surface proteins are used as the means to distinguish cell types. Unfortunately, many undesired cell types may also share the same cell surface receptors, which will badly compromise the efficiency of cell purification.
Hirohide Saito from the Center for iPS Cell Research and Application (CiRA) at Kyoto University has designed a new way to isolate differentiated cells using microRNAs. This technique appears to be better than using cell surface proteins and it may revolutionize stem cell science.
However, the protocols that are normally used to differentiate iPSCs lead to a mixed population of cells that are very heterogeneous, and the desired cell type has to be isolated from this mixture. Normally, antibodies that bind to surface receptors unique to the desired cell type are used for this purpose but in many cases such purification strategies are inefficient and the cell yield is rather poor. Also, these cell purification techniques have a tendency to damage cells
New RNA-based procedures designed at CiRA may avoid these problems. Hirohide Saito and his colleagues designed tiny RNA molecules (microRNAs or miRNAs) that are designed to detect and sort live cells not by surface receptors, but by miRNAs. MicoRNAs are better markers of cell types and can improve purity levels
Senior Lecturer Yoshinori Yoshida, a heart muscle specialist who works with Professor Saito, immediately saw the potential of this technology.
So Professor Saito and Dr. Yoshida put their heads together to test the effectiveness of miRNA switches
The results were remarkable. Dr. Yoshida saw far better purification than he ever seen with standard methods. Furthermore, because this technology is RNA-based, it does not integrate into the genome and cause mutations. This could potentially make the cells eligible for clinical application.
Just 3 advances from june, if you look the results from one year on Google, it's incredbile there's little breaktroughs every week for cheaper, safely, faster methods.
japanese bioenginereed HFs is coming guys, I definitly believe in a temporallu approval in 2018-2019. Then it will be our choice to take the risk or not ( but it will be low risk with the ipsc tumor-free development)
Scientists develop method to kill iPS-derived cells with high cancer risk
Researchers said July 21 they have found a way to eliminate cells derived from induced pluripotent stem (iPS) cells that have a high risk of becoming cancerous, a development that could lead to clinical applications of iPS cells.
“It is a totally new method that can remove cells that could turn cancerous,” said Kenichiro Kosai, a professor of gene therapy and regenerative medicine at Kagoshima University. “The technique could be used for clinical purposes in the field of regenerative medicine.”
pluripotent cells that fail to differentiate into a specific tissue are more likely to become cancerous, posing a grave problem for the clinical use of those cells.
Kosai and colleagues studied a gene known as survivin, which is activated in cancer cells. They discovered that survivin is also activated in iPS cells and ES cells that fail to develop into other cells.
The researchers created strains of a genetically modified virus that can proliferate and kill cells that contain survivin. Seven days after the modified virus was introduced into undifferentiated iPS cells and ES cells, all those cells died.
Meanwhile, cells that had turned into the specific tissue survived the introduction of the virus.
The research team will present its findings at a conference of the Japan Society of Gene Therapy on July 25 in Osaka."
That's a big big new, this will accelerate Tsuji, REgience, Keio univ, etc to enter human clinical trials
Other breaktroughts that will help, from only june/july 2015:
-New substrate opens door to mass produced regenerative thérapies
"Researchers at the University of Nottingham in the U.K., have found a synthetic substrate that can be used in the production of billions of stem cells.
Researchers at the University of Nottingham in the U.K. developed the cost-effective substrate that allows the growth of stem cells, and can also survive long-term storage.
"What we are doing here is paving the way for the manufacture of stem cells in large numbers when those therapies are proved to be safe and effective."
"The field of regenerative medicine has snowballed in the last five years and over the coming five years a lot more patients will be receiving stem cell treatments," Denning said. "Clinical trials are still in the very early stages. However, with this kind of product, if we can get it commercialized and validated by the regulators, it could be helping patients in two to three years." And he's from UK, not japan
- MicroRNA Switches Improve Cell Purification
Stem cell-based therapies usually require the differentiation of stem cells into various cell types that are used for regenerative therapies. Such a strategy requires that the differentiated cells be purified from the rest of the cells. Typically, cell surface proteins are used as the means to distinguish cell types. Unfortunately, many undesired cell types may also share the same cell surface receptors, which will badly compromise the efficiency of cell purification.
Hirohide Saito from the Center for iPS Cell Research and Application (CiRA) at Kyoto University has designed a new way to isolate differentiated cells using microRNAs. This technique appears to be better than using cell surface proteins and it may revolutionize stem cell science.
However, the protocols that are normally used to differentiate iPSCs lead to a mixed population of cells that are very heterogeneous, and the desired cell type has to be isolated from this mixture. Normally, antibodies that bind to surface receptors unique to the desired cell type are used for this purpose but in many cases such purification strategies are inefficient and the cell yield is rather poor. Also, these cell purification techniques have a tendency to damage cells
New RNA-based procedures designed at CiRA may avoid these problems. Hirohide Saito and his colleagues designed tiny RNA molecules (microRNAs or miRNAs) that are designed to detect and sort live cells not by surface receptors, but by miRNAs. MicoRNAs are better markers of cell types and can improve purity levels
Senior Lecturer Yoshinori Yoshida, a heart muscle specialist who works with Professor Saito, immediately saw the potential of this technology.
So Professor Saito and Dr. Yoshida put their heads together to test the effectiveness of miRNA switches
The results were remarkable. Dr. Yoshida saw far better purification than he ever seen with standard methods. Furthermore, because this technology is RNA-based, it does not integrate into the genome and cause mutations. This could potentially make the cells eligible for clinical application.
Just 3 advances from june, if you look the results from one year on Google, it's incredbile there's little breaktroughs every week for cheaper, safely, faster methods.
japanese bioenginereed HFs is coming guys, I definitly believe in a temporallu approval in 2018-2019. Then it will be our choice to take the risk or not ( but it will be low risk with the ipsc tumor-free development)
knowing something will be here soon makes me strong enough to stick to concealers, hair systems or whatever to hold on til the cure!! 
Comment